Recently, the international diabetes Federation (idF) estimated 371 million individuals are living with diabetes worldwide, including 50 % who remain undiagnosed. 1 The prevalence of diabetes is increasing in every country, 
a second analysis from the T1d Exchange clinic Registry demonstrated a direct relationship between SMBG frequency and a1c values, regardless of age or use of insulin pump versus injection. 8, 9 in contrast to the Type 1 diabetes population, the role of SMBG for patients with noninsulin-treated Type 2 diabetes is highly controversial, promoting substantial discussion, debate, and the conduct of numerous prospective and retrospective studies as well as meta-analyses to address this matter. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] overall, randomized controlled trials have yielded mixed results as to whether SMBG improves glycemic control in noninsulin-treated patients with Type 2 diabetes.
18,21-27 Systematic reviews and meta-analyses have demonstrated a consistently small (about 0.2-0.3 %) but statistically significant SMBG-derived improvement in a1c control among patients with Type 2 diabetes; however, the clinical relevance of such a modest improvement has been questioned, especially from a cost-benefit standpoint. Table 1 ). The major critique of the iSo 15197:2003 guidelines, which had been adopted by the Fda and other regulatory authorities, is that the 5 % (or one in 20) threshold was too high and therefore allowed for too many large, medically unacceptable errors. 37, 42 in the 2013 revision, this matter was addressed by a new requirement to address outliers, requiring that 99 % of readings fall within zones a and B of the survey-derived consensus Error Grid for Type 1 diabetes (see Figure 1 ).
The five zones (A, B, C, D, and E) of the Consensus Error Grid (CEG) are defined by estimated patient risk. © International Organization for Standardization (ISO) 2013 -all rights reserved. This figure is reproduced from ISO/Final Draft International Standard (FDIS) 15197 with permission of American National Standards Institute (ANSI) on behalf of ISO. This is a draft ISO document that is subject to change without notice and cannot be referred to or relied upon as an ISO standard.
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There has been an increasing amount of published literature characterizing the relative accuracy of commonly used SMBG [43] [44] [45] [46] [47] [48] [49] [50] and cGM 31,51,52 systems. 
Impact of Tighter SMBG Device Accuracy on Diabetes Care
With recognition that many commercially available SMBG devices were developed based on original iSo 15197:2003 standards, the iSo advised that a 36-month transition period be instituted before requiring mandatory compliance with the revised 2013 standards. 41 clearly, tighter standards will pose challenges for device manufacturers, particularly given the gamut of SMBG result-influencing factors (see Table 2 ), many of which cannot be controlled by manufacturers; thus, developing SMBG meters with continually improving accuracy may not necessarily be realistic. 34 one of the driving factors behind the new iSo 15197:2013 criteria is the notion that better performing SMBG devices will result in more accurate insulin dosing, which should translate into better patient outcomes. 41 however, although this rationale is logical, there currently is no head-to-head evidence demonstrating that differences in analytical accuracy between SMBG meters are associated with differences in clinical outcomes in Type 1 or 2 diabetes.
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The revised criteria also do not address the different accuracy needs of various patient groups. For example, noninsulin-treated patients may use SMBG as a general gauge (e.g. to periodically track their overall progress), while women with gestational diabetes or some hospitalized patients require tighter glycemic control and more accurate SMBG monitoring. 42, 53 although many portable over-the-counter SMBG devices are not intended or approved for hospital use, they are commonly used in this setting due to their convenience; 53 thus, tighter accuracy standards for general SMBG may also benefit the hospital setting. additionally, since current SMBG is used to calibrate cGM devices, it is imperative that SMBG accuracy be improved.
Recommendations for other SMBG aspects should also be considered.
Minimization of patient error could be addressed, e.g. with individually wrapped strips to maintain consistency and eliminate interference from humidity or high temperatures, which could effect SMBG readings. 36, 55 healthcare providers and patients could also benefit from standardized meter reporting, similar to electrocardiogram readings from different manufacturers. currently, every meter download looks different, and some reports are difficult to understand or have limited applicability. The need for standardized reporting and data analysis is highlighted in a summary report 
